Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Aldoxorubicin + ALT-803 + Avelumab + Cetuximab + ETBX-051 + ETBX-061 + GI-6301 + haNK cells|
|Synonyms||NANT chordoma vaccine combination|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|ALT-803||N-803|N803|Nogapendekin alfa|ALT803||ALT-803 (Nogapendekin alfa) is a fusion protein consisting a mutant IL-15 and a soluble IL-15Ra Fc, which activates and converts memory CD8+ T cells to effector immune cells with antitumor activity (PMID: 24404427, PMID: 31338557).|
|Aldoxorubicin||INNO-206|Doxorubicin-EMCH||Chemotherapy - Anthracycline 12||Aldoxorubicin (Doxorubicin-EMCH) is a derivative prodrug of doxorubicin that is converted to free doxorubicin within the acidic environment within tumors, and once converted, doxorubicin intercalates DNA, inhibits DNA synthesis and induces apoptosis (PMID: 30936721).|
|Avelumab||Bavencio||MSB0010718C||Immune Checkpoint Inhibitor 147 PD-L1/PD-1 antibody 86||Bavencio (avelumab) is a monoclonal antibody binds to human immunosuppressive ligand programmed death-ligand 1 (PD-L1, CD274) and blocks protein signaling, resulting in immune regulation and antitumor immunity (PMID: 26014098). Bavencio (avelumab) is FDA-approved for use in adult and pediatric patients of 12 years or older with metastatic Merkel cell carcinoma, as maintenance therapy in locally advanced or metastatic urothelial carcinoma (UC), in locally advanced or metastatic UC that progressed following chemotherapy, and in combination with axitinib as first-line therapy in advanced renal cell carcinoma (FDA.gov).|
|Cetuximab||Erbitux||IMC-C225||EGFR Antibody 39||Erbitux (cetuximab) is a monoclonal antibody directed against EGFR, which inhibits signal transduction and cell proliferation (PMID: 28695301). Erbitux (cetuximab) is FDA approved for use in head and neck squamous cell carcinoma and KRAS wild-type, EGFR positive colorectal cancer (FDA.gov).|
|ETBX-051||ETBX051|ETBX 051||ETBX-051 is a virally based vaccine that infects cells and induces expression of the brachyury protein protein, which may activate the immune system to elicit a cytotoxic T-lymphocyte (CTL) response against brachyury expressing tumor cells (PMID: 31594913).|
|ETBX-061||ETBX061|ETBX 061||ETBX-061 is a virally based vaccine that infects cells and causes expression of the Muc1 protein, which may activate the immune system to elicit a cytotoxic T-lymphocyte (CTL) response against Muc1 expressing tumor cells (PMID: 31594913).|
|GI-6301||GI-6301 is a cancer vaccine that activates immune response against tumor cells (PMID: 26130065).|
|haNK cells||CD16.158V ER IL-2|NK-92 cells||haNK cells are natural killer cells, specifically from the NK-92 cell line, that have been engineered to express IL-2 and the CD16 allele, and when combined with other therapies such as an immunotherapy can synergistically enhance antibody-dependent cell-mediated cytotoxicity (PMID: 28477372).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03647423||Phase Ib/II||Aldoxorubicin + ALT-803 + Avelumab + Cetuximab + ETBX-051 + ETBX-061 + GI-6301 + haNK cells||QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.||Withdrawn||USA||0|